Very Very positive IMO
Motor Neurone Disease Phase 1/2 Clinical Trial Update
• All 12 patients in Cohort 3 have received initial escalated dose of MPL
• The dosages used for Cohorts 1, 2 & 3 have been well tolerated, and no Serious
Adverse Events were observed, implying the drug has a good safety profile
• Analysis evaluating changes in biomarkers and pharmacodynamics is well
underway
• PharmAust expects to proceed to Phase 2 with favourable efficacy biomarker
results under the interim analysis
27 June 2023 – Perth, Australia: PharmAust Limited (ASX: PAA & PAAO), a clinical-stage
biotechnology company, is pleased to announce that all 12 patients in Cohort 3 have received an initial
escalated dose in its Phase 1/2 clinical trial of its lead drug candidate monepantel (MPL) in Motor
Neurone Disease/Amyotrophic Lateral Sclerosis (MND/ALS).
The patients are enrolled at two sites: Calvary Health Care Bethlehem, Statewide Progressive
Neurological Disease Service, Caulfield South in Victoria and The Centre for Motor Neurone Disease
Research, Faculty of Medicine and Health Research Macquarie University in NSW.
The Phase 1/2 clinical study aims to determine the tolerability, safety, pharmacokinetics and preliminary
efficacy of oral MPL in individuals living with MND. The trial is open label and comprises four cohorts
with escalating MPL doses.
So far the MPL tablets have been well tolerated by all patients in the trial and the Safety Monitoring
Committee will continue the assessment of safety and efficacy for each dosage.
Progress update on Phase 1/2 MND interim analysis
As previously announced, interim analysis of biomarkers and pharmacodynamics through the current
Phase 1/2 study is well underway. These highly specialised assays are being performed by three
independent Australian institutions to explore how MPL is acting on the mTOR signalling pathway in
MND patients to slow disease progression. It is hoped that biomarker analysis will confirm MPL’s ability
to cross the blood-brain barrier and to aid in clearing protein aggregation that is the hallmark of
neurodegenerative diseases through the induction of autophagy in nerve cells.
Biomarker research in MND has led to the identification of the protein p75 ECD in urine, demonstrating
people with MND show significantly higher levels of that protein compared to those without MND
(reference: https://pubmed.ncbi.nlm.nih.gov/28228570/).
The p75 ECD study results have now been received from Flinders University in Adelaide and will be
formally interpreted by a pharmacologist and will be announced as soon as possible.
An analysis being conducted at the Florey Institute in Melbourne evaluating p-RPS6KB1 and pEIF4EBP1 is still pending. Further, highly specialised testing of Neurofilament Light Chain (NfL) is being
conducted at the University of Tasmania which is expected in the coming weeks.
PharmAust Limited ABN 35 094 006 023. Suite 116, 1 Kyle Way, Claremont, Western Australia
Tel: 08 9202 6814 Fax: 08 9467 6111
www.pharmaust.com
About Motor Neurone Disease/Amyotrophic Lateral Sclerosis and the trial
According to the International Alliance of ALS/MND Associations, MND affects over 350,000 people
globally and kills more than 100,000 people yearly. The disease is invariably fatal, with the average life
expectancy of someone with MND being around 27 months. The MND/ALS addressable market is
US$3.6Bn per annum, with Riluzole reaching ~US$1Bn annual sales.
The disease is progressive, meaning the symptoms get worse over time. MND has no cure and no
effective treatment to reverse its progression. PharmAust notes that five patients have surpassed the
8-month mark on MPL without any safety issues, and one patient appears “stable”.
PharmAust demonstrated in its preclinical programs that MPL has the potential to activate molecular
pathways relevant to the treatment of MND. MPL could reduce the rate of degeneration and loss of
motor neurons in the brainstem's anterior horns and motor nuclei. There are also several surrogate
clinical endpoints to be determined during the trial. PharmAust has developed and manufactured a
bespoke MPL tablet for the trial.
The Phase 1/2 study is being funded by a commitment of $881,085 by FightMND, Australia's largest
independent funder of MND research.
With success in the clinic, PharmAust hopes that MPL could receive orphan drug designation by the
TGA and FDA for MND. Such designations come with financial and supportive benefits and PAA is
evaluating this opportunity.
This announcement is authorised by the Board.
Enquiries:
Anusha Aubert
Investor Relations
[email protected]
P +61 (8) 9202 6814
F +61 (8) 9467 6111
W www.pharmaust.com
- Forums
- ASX - By Stock
- PAA
- Ann: Motor Neurone Disease Phase 1/2 Clinical Trial Update
Ann: Motor Neurone Disease Phase 1/2 Clinical Trial Update, page-3
-
- There are more pages in this discussion • 163 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAA (ASX) to my watchlist
(20min delay)
|
|||||
Last
22.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $86.90M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 51393 | 22.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
21.0¢ | 25000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 51393 | 0.225 |
2 | 263127 | 0.220 |
1 | 2325 | 0.215 |
7 | 47261 | 0.210 |
5 | 198228 | 0.205 |
Price($) | Vol. | No. |
---|---|---|
0.210 | 25000 | 1 |
0.220 | 100000 | 1 |
0.230 | 43928 | 4 |
0.240 | 44200 | 1 |
0.245 | 55000 | 4 |
Last trade - 10.07am 07/05/2024 (20 minute delay) ? |
Featured News
PAA (ASX) Chart |
Day chart unavailable
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, CEO
Steven Gourlay
CEO
Previous Video
Next Video
SPONSORED BY The Market Online